Here’s What Analysts Are Saying About Envista (NVST)

Envista Holdings Corporation (NYSE:NVST) is one of the 10 Best Medical Stocks to Buy Under $30. On April 24, Morgan Stanley raised its price target on Envista Holdings Corporation (NYSE:NVST) from $19 to $21 while maintaining an Equal Weight rating on the stock.

The research firm noted that its US dental survey indicates weaker practice volumes during the first quarter. However, Morgan Stanley told investors that demand in the Specialty segment, which includes clear aligners and implants, improved slightly.

Earlier, on April 15, Citi analyst Daniel Grosslight initiated coverage of Envista Holdings Corporation (NYSE:NVST), giving the stock a Neutral rating and setting the price target at $29.

The research firm began coverage of the animal health and dental sector with a “cautiously optimistic” view. Citi prefers the animal health group sector, noting that the pet “humanization” trend should drive increased spending. The research firm pointed out that the dental sector is facing pressure because of a weak economic environment. Citi expects customers to shift toward lower-cost implants and orthodontic products and services.

Envista Holdings Corporation (NYSE:NVST) is a global dental products company that holds a portfolio of more than 30 brands. The company focuses on dental implants and treatment options, orthodontics, and digital imaging technologies.

READ NEXT: 10 Best Fintech Stocks to Invest In According to Billionaires and 10 Unrivaled Stocks of the Next 5 Years.

Disclosure: None.  Follow Insider Monkey on Google News.